We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis.
- Authors
Jézéquel, P.; Campion, L.; Joalland, M.-P.; Millour, M.; Dravet, F.; Classe, J.-M.; Delecroix, V.; Deporte, R.; Fumoleau, P.; Ricolleau, G.
- Abstract
This study screened large cohorts of node-positive and node-negative breast cancer patients to determine whether the G388R mutation of the FGFR4 gene is a useful prognostic marker for breast cancer as reported by Bange et al in 2002. Node-positive (n=139) and node-negative (n=95) breast cancer cohorts selected for mutation screening were followed up for median periods of 89 and 87 months, respectively. PCR - RFLP analysis was modified to facilitate molecular screening. Curves for disease-free survival were plotted according to the Kaplan - Meier method, and a log-rank test was used for comparisons between groups. Three other nonparametric linear rank-tests particularly suitable for investigating possible relations between G388R mutation and early cancer progression were also used. Kaplan - Meier analysis based on any of the four nonparametric linear rank tests performed for node-positive and node-negative patients was not indicative of disease-free survival time. G388R mutation of the FGFR4 gene is not relevant for breast cancer prognosis.British Journal of Cancer (2004) 90, 189-193. doi:10.1038/sj.bjc.6601450 www.bjcancer.com
- Subjects
BREAST cancer; TUMOR markers; GENETIC mutation; PROTEIN-tyrosine kinases; CANCER prognosis; PROGNOSIS
- Publication
British Journal of Cancer, 2004, Vol 90, Issue 1, p189
- ISSN
0007-0920
- Publication type
Article
- DOI
10.1038/sj.bjc.6601450